(BIIB) Biogen Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BIIB) Biogen Inc. Bundle
Visual. Strategic. Downloadable.
This Biogen Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The content on this page is a real preview of the actual report, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
LEQEMBI, early Alzheimer’s antibody
LEQEMBI is Biogen’s key growth launch with Eisai, now approved in the U.S., Japan and China for early Alzheimer’s. The addressable U.S. market alone is about 6.9 million people age 65+, and it keeps expanding as diagnosis and biomarker testing improve. If uptake holds, LEQEMBI has the clearest path to a multibillion-dollar long-term franchise.
QALSODY, SOD1-ALS treatment
QALSODY is the first approved therapy for SOD1-ALS, a rare group that accounts for about 2% of ALS cases. Biogen can still defend share because there is no direct like-for-like rival today, and its medical edge stays strong in a high-unmet-need niche. In Biogen's 2025 reporting, it remained an early but strategic growth asset.
ZURZUVAE, postpartum depression launch
ZURZUVAE gives Biogen entry into postpartum depression, a U.S. market tied to about 1 in 8 mothers after birth. It sits in a growing neuropsychiatry niche with room to expand, so it can act like a Star if uptake holds. Value depends on faster diagnosis, payer access, and more prescriber comfort with a 14-day oral course.
BENEPALI, etanercept biosimilar
BENEPALI, the etanercept biosimilar, stays a star in Biogen Inc.’s biosimilar mix because it holds strong share in Europe, where payers keep steering use toward lower-cost anti-TNF options. That makes it a high-share, high-growth BCG fit, even as pricing pressure stays tight.
Biogen Inc.’s biosimilar base is still a real growth engine, and BENEPALI helps defend that spot through broad substitution and payer-led switching in key EU markets.
- Strong Europe share
- Payer-driven switch to biosimilars
- High-share BCG star
IMRALDI, adalimumab biosimilar
IMRALDI sits in a big adalimumab biosimilar market still expanding after Humira lost US exclusivity in 2023 and EU erosion kept pushing price cuts. AbbVie’s Humira still posted about $9.3 billion in 2024 sales, showing the scale of switching pools. Biogen can use its commercial reach to win payer contracts and drive volume.
- Big market, strong switch demand
- Price cuts keep adoption high
- Biogen scale supports access
Biogen’s Growth Drivers: LEQEMBI Leads the Way
Biogen Inc.’s Stars are led by LEQEMBI, with U.S., Japan, and China approvals and a U.S. addressable market of about 6.9 million people age 65+. QALSODY keeps a first-mover edge in SOD1-ALS, a rare group of about 2% of ALS cases. ZURZUVAE adds a growing postpartum depression niche, while BENEPALI and IMRALDI support Biogen’s biosimilar growth in Europe.
| Asset | Star case |
|---|---|
| LEQEMBI | Large, expanding Alzheimer’s market |
| QALSODY | First-in-class SOD1-ALS |
| ZURZUVAE | Growing postpartum depression use |
| BENEPALI/IMRALDI | EU biosimilar share and switching |
What is included in the product
Detailed Word Document
Biogen’s BCG Matrix maps its portfolio to guide invest, hold, or divest choices across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page Biogen Inc. BCG Matrix to quickly spot each unit’s quadrant and simplify portfolio decisions
Reference Sources
Supports confidence in Biogen Inc. decisions by showing credible, traceable sources behind the key assumptions and numbers.
Cash Cows
TYSABRI, long-running MS franchise
TYSABRI is a classic cash cow for Biogen Inc.: a mature MS brand with durable demand and low incremental launch spend. In Biogen Inc.’s 2025 filings, it still ranked among the company’s core revenue products, backed by a long track record of more than $1 billion in annual sales in prior years. MS growth is limited, but the franchise keeps strong share in a well-known indication and continues to throw off cash.
SPINRAZA, SMA market leader
SPINRAZA is Biogen Inc.'s established SMA leader and a classic cash cow: despite a mature market, it still has a large installed base, strong brand recognition, and durable demand. Biogen has said SPINRAZA has generated over $1 billion in annual sales in recent years, showing its ongoing cash power even as competition rises.
RITUXAN, mature anti-CD20 brand
RITUXAN is a mature anti-CD20 brand tied to long-used hematology and rheumatology indications, so it still throws off steady cash for Biogen Inc. Roche reported CHF 6.49 billion in 2024 sales for MabThera/Rituxan, a sign of large but low-growth demand. With decades of clinical use and broad physician familiarity, it fits the cash cow profile: high share, slow growth, dependable cash flow.
RITUXAN HYCELA, subcutaneous oncology product
RITUXAN HYCELA is a mature subcutaneous oncology product with a fixed 1,400 mg rituximab plus 23,400 units hyaluronidase dose, used in a narrow, established niche after IV rituximab induction. It is supported by entrenched prescribing habits, not fast volume growth, so the role is mainly cash extraction. The product fits a Cash Cow slot because the market is stable and switching costs are high.
- Fixed-dose, mature niche product
- Driven by repeat prescribing patterns
- Low growth, steady cash generation
GAZYVA, CLL and follicular lymphoma
GAZYVA fits a Cash Cow profile: CLL and follicular lymphoma are mature, recurring-use markets, not a fresh launch wave. CLL is the most common adult leukemia, and follicular lymphoma makes up about 20% of non-Hodgkin lymphoma cases, so demand stays steady. If Biogen keeps selling costs lean, this asset can keep generating cash.
- Stable, repeat oncology demand
- Mature market, low growth
- Cash stays strong if costs stay tight
Biogen’s Cash Cows Keep the Revenue Engine Running
Biogen Inc.'s cash cows are mature brands with steady demand and low launch spend. TYSABRI and SPINRAZA still anchor cash flow, each with over $1 billion in annual sales in recent years.
| Brand | Role | Signal |
|---|---|---|
| TYSABRI | Cash cow | High share, slow growth |
| SPINRAZA | Cash cow | Installed base, repeat use |
RITUXAN and GAZYVA add stable, recurring revenue from mature oncology use.
Preview Before You Purchase
Biogen Inc. Reference Sources
The Biogen Inc. BCG Matrix preview you see is the exact same document you’ll receive after purchase. No mockups, no demo pages—just the full, ready-to-use report. Once purchased, it’s instantly available for your own analysis, editing, or presentation.
Dogs
TECFIDERA, generic-pressured MS brand
TECFIDERA is a Dogs asset for Biogen Inc. because its U.S. exclusivity ended in 2020, and generics quickly crushed the franchise. Biogen reported TECFIDERA revenue at about $0.3B in 2024, far below its peak, showing the steep loss of share and growth. It is now a low-return legacy MS brand with weak pricing power and limited strategic value.
AVONEX, older interferon therapy
AVONEX, launched in 1996, is an aging multiple sclerosis brand with fading relevance in Biogen Inc.'s portfolio. Newer therapies have taken share over time, so it sits firmly in the Dogs box: low growth, low share, and limited strategic upside. Its sales base is now a small, shrinking part of the MS business, which supports a harvest-or-exit view.
PLEGRIDY, declining interferon option
PLEGRIDY stays stuck in the crowded interferon MS class, so Biogen gets little growth lift from it. The brand looks more like a maintenance asset than a driver, with low momentum and heavy competition from higher-efficacy MS options. In BCG terms, it fits a Dog: weak share, weak growth.
FAMPYRA, narrow MS supportive treatment
FAMPYRA is a narrow MS add-on for walking problems, with a 10 mg twice-daily dose and a short trial period to find responders. That limits its reach, so the addressable market stays small and growth is slow versus Biogen Inc.'s larger MS and rare-disease franchises.
- Symptomatic, not disease-modifying
- Small responder pool
- Low strategic momentum
- Fits Dogs in the BCG Matrix
ADUHELM, discontinued Alzheimer’s asset
ADUHELM is a clear dog for Biogen Inc. It was voluntarily discontinued in January 2024 after failing to build durable share, and it never became a steady growth engine. Its fast fade and controversy made it a commercial and reputational drag, not a platform asset.
- Discontinued in January 2024
- No durable market share
Biogen’s Dogs: Legacy assets fading under generic and market pressure
Biogen Inc.’s Dogs are legacy, low-growth assets with weak share and little strategic lift. TECFIDERA fell to about $0.3B in 2024 after generic erosion, while AVONEX and PLEGRIDY stayed trapped in mature interferon MS markets. FAMPYRA remained niche, and ADUHELM was discontinued in January 2024.
| Asset | Dog signal | Latest data |
|---|---|---|
| TECFIDERA | Generic hit | ~$0.3B 2024 sales |
| ADUHELM | Exited | Stopped Jan 2024 |
Question Marks
BIIB080, tau-targeting Alzheimer’s candidate
BIIB080 targets tau, a key driver in Alzheimer’s, which affects about 7.2 million Americans in 2025 and creates a huge unmet need. Biogen’s asset is still early, so it has not built market share yet and still needs clinical proof and physician adoption. That makes it a clear question mark: high upside, but success is not established.
BIIB059, lupus and immune-neurology candidate
BIIB059 sits in a tough lupus/immune-neurology niche with high unmet need: lupus affects about 5 million people worldwide, and treatment response is still uneven. It is a classic Question Mark in Biogen Inc. BCG Matrix Analysis because the asset can be meaningful, but it is still unproven and needs clear clinical edge.
Success will depend on showing better efficacy and safety than current immunology options, plus winning payer access in a market where biologic pricing is tightly managed. Until late-stage data and regulatory traction are clear, BIIB059 remains high-potential but not yet a cash generator for Company Name.
DAPIROLIZUMAB PEGOL, lupus program
Dapirolizumab pegol is a Question Mark for Biogen Inc.'s lupus bet because it targets systemic lupus erythematosus, a disease affecting about 5 million people worldwide. The market is attractive, but it is crowded and hard to win, with only a few approved lupus drugs and high trial failure risk. It needs heavy R&D spend and clear late-stage data before it can shift from a cash drain to a leader.
BIIB122, Parkinson’s disease program
BIIB122 is a Parkinson’s disease asset in Biogen Inc.’s pipeline, so it has no current market share yet. That fits a question mark: the addressable market is large, with Parkinson’s affecting more than 10 million people worldwide, but value depends on clinical success and launch timing.
Biogen Inc. is still investing in development, so BIIB122 can become meaningful only if it proves strong efficacy and safety in late-stage trials.
- Large market, zero current share
- High upside, high trial risk
- Question mark in BCG terms
BIIB131, acute neurological events program
BIIB131 is a Question Mark in Biogen Inc. because it targets acute neurological events in a high-need CNS space, but it has no market share yet and no disclosed product revenue. If clinical data are strong, the upside can be large; if not, the program stays a cash drain under Biogen Inc.’s R&D spend. For now, it is a high-risk bet, not a proven asset.
- No sales, no share
- High unmet CNS need
- Upside depends on data
- Still consumes cash
Biogen’s Big Bets: Zero Sales, Huge 2025 Potential
Biogen Inc.’s Question Marks are BIIB080, BIIB059, dapirolizumab pegol, BIIB122, and BIIB131: all have zero current sales, but target huge 2025 markets like Alzheimer’s, lupus, and Parkinson’s.
They can only move up if late-stage data beat today’s standards and win payer access; until then, they stay R&D cash uses, not cash generators.
| Asset | 2025 market | Status |
|---|---|---|
| BIIB080 | 7.2M US Alzheimer’s | Unproven |
| BIIB122 | 10M+ Parkinson’s | Zero share |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.